BR

Brazil

BR

South America

Regulatory Overview

Brazil is regulated by the ANVISA. The country has 1 documented regulatory pathway for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

ANVISA

Regulatory Pathways (1)

ANVISA's expanded access program allows use of unapproved drugs for patients with serious or life-threatening diseases who have no therapeutic alternatives among registered products.

Application Form: ANVISA EAP Petition
Legal Basis: RDC 204/2017
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: ANVISA Expanded Access Regulations

Drugs Available (43)

DrugAccess RouteStatusLead Time
furosemide
tamoxifen citrate
metoprolol
carbamazepine
diethylcarbamazine
minoxidil
gabapentin
phacoemulsification surgery
ascorbic acid
Digoxin
Retinoids (Tretinoin)
aspirin
Valproic Acid
folic acid
Acetazolamide
vutrisiran
Angiotensin-Converting Enzyme Inhibitors (Enalapril)
levothyroxine sodium
ivermectin
insulin
rituximab
allopurinol
Topical corticosteroids
Erythromycin
Doxycycline
avalglucosidase alfa
metformin
Methotrexate
Levetiracetam
prednisone
Insulin glargine
aflibercept
acetaminophen
riboflavin
bevacizumab
celecoxib
Biotin
Zidovudine
emollients with keratolytics
Tamoxifen
Artificial tears (Hypromellose)
Ribavirin
Amnioreduction
BR
Brazil
ISO CodeBR
RegionSouth America
Regulatory AuthorityANVISA
Pathways1 documented
Drugs Available43 drug(s)